No. of Recommendations: 5
I owned WTM in the past thanks to Jim pointing it out. Two interesting events at WTM:
https://investor.whitemountains.com/news-releases/...Bamboo was launched in 2018 by John Chu, a seasoned insurance executive. Bamboo provides homeowners' insurance for over 100,000 California policyholders, using its technology-enabled underwriting platform to select and manage risk. Bamboo has grown profitably and rapidly in the challenging California market and is now poised to expand into other states.
https://investor.whitemountains.com/news-releases/...John J. Daly, a former founding member and principal of Alleghany Capital, has joined WM Partners as CEO and Managing Partner. The business will seek to establish majority positions in companies with $10 to $50 million of EBITDA and intends to deploy up to $500 million of equity capital over time.
And two companies that still have explosive sales growth that I'm looking at (via Barron's):
Citi analyst Andrew Baum wrote that Eli Lilly's diabetes drug Mounjaro, still awaiting approval for weight loss, could eventually reach peak sales of around $60 billion, with $37 billion in sales coming from weight loss treatment. Lilly's third-quarter sales are expected to rise 29%, according to FactSet.
Lilly's Mounjaro is competing with Novo Nordisk's weight-loss drug Wegovy and its diabetes treatment cousin Ozempic. Novo Nordisk has become the biggest European company by value since the Ozempic phenomenon. Third-quarter sales are expected to rise 34%, FactSet said.
Trying to hit near the bottom in beaten up stocks like INTC and DG can be profitable.
